Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Emory University, Winship Cancer Institute details research in cancer gene therapy
September 9th, 2008
New research, 'Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors,' is the subject of a report. "The aim of this study is to investigate the efficacy of a novel Akt inhibitor, perifosine, in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human myeloma cells and primary patient samples. The activity of perifosine in combination with TRAIL was evaluated with experiments testing the effect of perifosine on DR4/DR5 expression by the use of chimeric blocking antibodies, as well as siRNA," scientists writing in the journal Clinical Cancer Research report. "DR4 and DR5...
Source: Cancer Weekly (2008-09-09)
|
